FOLR1 and neoplasm: FRα also facilitates resistance to chemotherapy in OC patients, since its higher expression on tissues is associated with a lower response rate to mitotic agents; furthermore, protein expression on the tumor surface is not affected by chemotherapy, which makes it an ideal TAA for targeted immunotherapy treatment.